Key Points
- Johnson & Johnson EVP Elizabeth Forminard sold 15,918 shares at an average price of $257, generating $4.09 million. Her remaining direct stake fell by 48.37% to 16,994 shares.
- JNJ’s latest quarter exceeded expectations, with $2.90 in EPS versus the $2.84 consensus and revenue of $25.31 billion, up 6.6% year over year. The company reaffirmed fiscal 2026 EPS guidance of $11.60–$11.75.
- The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.1% annualized yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $268.22.
Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Johnson & Johnson Stock Up 0.8%
JNJ stock opened at $259.03 on Friday. The firm has a market cap of $624.23 billion, a PE ratio of 30.01, a PEG ratio of 2.45 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm's 50 day moving average price is $248.47 and its 200-day moving average price is $239.73. Johnson & Johnson has a one year low of $170.39 and a one year high of $274.90.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm's quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson's dividend payout ratio is currently 62.11%.
Trending Headlines about Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Dividend appeal remains a key support. Recent coverage highlights JNJ as a blue-chip income stock with a long record of dividend growth and defensive fundamentals, which may attract investors seeking stability amid elevated interest rates. Why is Johnson & Johnson drawing dividend attention today? Top dividend stocks to buy and hold
- Positive Sentiment: Reported talc settlement removes a major legal overhang. JNJ agreed to a reported $5.5 billion settlement covering tens of thousands of talc lawsuits. While costly, resolving the claims could improve legal and financial visibility and reduce uncertainty surrounding the company. Johnson & Johnson reaches $5.5 billion talc settlement
- Positive Sentiment: Citi issued a Buy rating, adding to the favorable analyst backdrop. JNJ’s latest reported quarter also exceeded expectations, with revenue rising 6.6% year over year and earnings surpassing consensus estimates. Johnson & Johnson gets a Buy from Citi
- Neutral Sentiment: Coverage says JNJ has remained steady during a division transition. The company is also investing more than $1 billion to expand U.S. contact-lens production, a potential long-term growth initiative, although near-term returns remain uncertain. Why Johnson & Johnson is steady amid a division transition
- Negative Sentiment: The talc agreement represents a substantial cash and earnings burden, and investors may continue evaluating whether the settlement fully resolves future claims and related costs.
Hedge Funds Weigh In On Johnson & Johnson
Several institutional investors have recently modified their holdings of the business. Harborfront Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $130,000. Pension & Wealth Management Advisors Inc. boosted its holdings in Johnson & Johnson by 14.0% in the second quarter. Pension & Wealth Management Advisors Inc. now owns 2,069 shares of the company's stock valued at $526,000 after purchasing an additional 254 shares during the period. Citizens Financial Group Inc. RI boosted its holdings in Johnson & Johnson by 1.9% in the second quarter. Citizens Financial Group Inc. RI now owns 210,648 shares of the company's stock valued at $53,498,000 after purchasing an additional 3,848 shares during the period. Aegis Wealth Management LLC grew its stake in Johnson & Johnson by 4.3% during the 2nd quarter. Aegis Wealth Management LLC now owns 2,583 shares of the company's stock worth $656,000 after purchasing an additional 106 shares in the last quarter. Finally, UNIVEST FINANCIAL Corp increased its holdings in Johnson & Johnson by 1.4% during the 2nd quarter. UNIVEST FINANCIAL Corp now owns 69,498 shares of the company's stock worth $17,650,000 after purchasing an additional 985 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.
Analysts Set New Price Targets
Several analysts recently issued reports on the stock. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 15th. Johnson Rice reaffirmed a "buy" rating on shares of Johnson & Johnson in a research note on Monday. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Scotiabank restated an "outperform" rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a "market perform" rating in a research report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $268.22.
Check Out Our Latest Research Report on Johnson & Johnson
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
